Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;62(9):2633-9.
doi: 10.1002/art.27570.

Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis

Jason R Kolfenbach  1 , Kevin D Deane, Lezlie A Derber, Colin I O'Donnell, William R Gilliland, Jess D Edison, Antony Rosen, Erika Darrah, Jill M Norris, V Michael Holers
Affiliations

Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis

Jason R Kolfenbach et al. Arthritis Rheum. 2010 Sep.

Abstract

Objective: To determine whether antibodies against peptidyl arginine deiminase type 4 (PAD-4) are present in the preclinical phase of rheumatoid arthritis (RA) and to compare the timing and extent of their appearance with those of other preclinical autoantibodies.

Methods: Prediagnosis serum samples from 83 patients with RA were evaluated for the presence of anti-PAD-4 antibody, anti-cyclic citrullinated peptide (anti-CCP) antibody, and rheumatoid factor. In addition, a control cohort (n = 83) matched by age, sex, race, number of serum samples, and duration of serum storage was tested for the presence of anti-PAD-4 antibody to determine its sensitivity and specificity for the subsequent development of RA.

Results: Fifteen of 83 patients with RA (18.1%) had at least 1 prediagnosis sample positive for anti-PAD-4. One of 83 control subjects (1.2%) had at least 1 positive sample, resulting in a sensitivity and specificity of 18.1% and 98.8%, respectively, of anti-PAD-4 for the future development of RA. The mean duration of anti-PAD-4 positivity prior to clinical diagnosis was 4.67 years. Anti-PAD-4 positivity was associated with anti-CCP positivity (odds ratio 5.13 [95% confidence interval 1.07-24.5]). In subjects with prediagnosis samples that were positive for both antibodies, anti-CCP positivity predated anti-PAD-4 positivity in 9 of 13 cases (69%).

Conclusion: Autoantibodies to PAD-4 are present during the preclinical phase of RA in a subset of patients and are associated with anti-CCP positivity. Further exploration is needed regarding the timing of appearance and disease-related effects of PAD-4 autoimmunity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Longitudinal Pattern of PAD4 and CCP Antibodies in 15 RA Patients with Pre-Clinical Anti-PAD4
Testing performed for anti-PAD-4 and anti-CCP antibody in successive samples within each individual. Time between samples varied among subjects and is not reflected in this figure. CCP titers separated in to the following categories: 0 (0 – 5 U/mL), 1 (>5 – 50 U/mL), 2 (>50 – 100 U/mL), 3 (>100 – 150 U/mL), and 4 (>150 U/mL). PAD-4 antibody level determined by semiquantitative scale based upon densitometry (0–3). × Anti-PAD-4 Antibody (0–3) formula image Anti-CCP Antibody (0–4)
See this image and copyright information in PMC

References

    1. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48(10):2741–9. - PubMed
    1. Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis. Ann Rheum Dis. 2006;65(4):535–7. - PMC - PubMed
    1. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–6. - PubMed
    1. Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Annals of the Rheumatic Diseases. 2008;67(6):801–7. - PMC - PubMed
    1. Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18(9):1282–4. - PubMed

Publication types